BMS divests its BMS-387032 and BMS-604992 to Sunesis and Elixir. These out-licensing deals did not have much impact on BMS’ share price, but help BMS to survive the revenue loses from patent expires, to restructure the company and focus on the disease areas where it can attain long-standing leadership and have a profit-making opportunity. Likewise, picking up the cast-offs from larger companies may prove a booming approach for both Sunesis and Elixir.